Transdermal delivery of drugs

Indian Journal of Pharmacology

Volumn 29, Issue 3, 1997, Pages 140-156

  Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Controlled release; Penetration and permeation; Transdermal delivery

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ALCOHOL DERIVATIVE; ALPHA INTERFERON; ANTIBODY; ASPARTAME; CLONIDINE; COLLAGEN; CYCLOSPORIN; DEPONITE; DRUG VEHICLE; ENZYME; ESTRADIOL; FATTY ACID; FENTANYL; GLYCERYL TRINITRATE; GLYCOL; HORMONE; ISOSORBIDE DINITRATE; LAUROCAPRAM; NAPROXEN; NICOTINE; POLYMER; PROTEIN HYDROLYSATE; SCOPOLAMINE; SERUM ALBUMIN; SULFOXIDE; SURFACTANT; TOP NITRO; TRANSDERM TTS; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VACCINE; VASOPRESSIN;

ANGINA PECTORIS; BLOOD FLOW; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; COST; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG METABOLISM; ELECTROPORATION; HUMAN; IONTOPHORESIS; MATHEMATICAL MODEL; NONHUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; SKIN; SKIN PERMEABILITY; STRATUM CORNEUM; SUBLINGUAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030793498     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (165)

1. Barr M. Percutaneous absorption. J Pharm Sci 1962; 61:395-409.
2. Baker H. The skin as barrier. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton JL, eds. Text Book of Dermatology. Vol. I, 4th ed. Oxford: Blackwell Scientific Publications, 1986:355-66.
3. Ritschel WA, Hussain AS. The principles of skin permeation. Meth Find Exptl Clin Pharmacol 1988;10:39-56.
4. Chein YW. Advances in transdermal systemic drug delivery. Drugs of Future 1988;13:343-62.
5. Williams ML, Elias PM. The extracellular matrix of stratum corneum: Role of lipids in normal and pathological function. Cnt Rev Ther Drug Carr Sys 1989;3:95-122.
6. Moghimi HR, Williams AC, Barry BW. A lamellar matrix model for stratum corneum intercellular lipids. II. Effect of geometry of startum corneum on permeation of model drugs 5-fluorouracil and oestradiol. Int J Pharm 1996;131: 116-29.
7. Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983;80:44s-9s.
8. Golden GM, McKie JE, Potts RO. Role of stratum corenum lipid fluidity in transdermal flux. J Pharm Sci 1987;76:25-8.
9. Imokawa G, Hatton M. A possible functions of structural lipids in water-holding properties of stratum corneum. J Invest Dermatol 1985;84:282-4.
10. Grayson S, Elias PM. Isolation and lipid biochemical characterization of stratum corneum membrane complexes: Impilications for cutaneous permeability. J Invest Dermatol 1982;78:128-35.
11. Barry BW. Dermatological Formulations. Percutaneous Absorption. New York: Marcel Dekker, 1983:95-120,138-139,144,128-233.
12. Moghimi HR, Williams AC, Barry BW. A lamellar matrix model for stratum corneum intercellular lipids. I. Characterization and comparison with startum coreneum intercellular structure. Int J Pharm 1996;131:103-15.
13. Blank IH, Scheuplien RJ, McFarlane DJ. Mechanism of percutaneous absorption III. The effect of temperature on transport of non electrolytes across skin. J Invest Dermatol 1967;49:582-9.
14. Barry BW. Lipid-protein-partition theory of skin penetration enhancement. J Cont Rel 1991;15:237-48.
15. Barry BW. Mode of action of penetration enhancers in human skin. J Cont Rel 1987;6:85-97.
16. Houk J, Guy RH. Membrane models for skin penetration studies. Chem Rev 1988;88:455-71.
17. Franz TJ, Tojo K, Shah KR, Kydonieus A, Transdermal delivery. In: A Kydonieus, ed. Treatise on Controlled Drug Delivery. New York: Marcel Dekker, 1992:341-421.
18. 14C-cortisol in man. J Invest Dermatol 1967;48:181-3.
19. Elias PM. Lipids and the epidermal permeability barrier. Arch Dermatol Res 1981;270:95-117.
20. Behl CR, Bellantone NH, Flynn GL. Influence of age on percutaneous absorption of drug substances. In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption. New York: Marcel Dekker, 1985:183-212.
21. Ritschel WA. Applied Biopharmaceutics. University of Cincinnati, Cincinnati, OH, 1971:1229-44.
22. Menczel E. Delipidization and percutaneous absorption, In: Bronaugh RL, Maibach HI, eds. Percutaneous Absorption. New York: Marcel Dekker, 1985:133-9.
23. Wiedmann TS. Influence of hydration on epidermal tissue. J Pharm Sci 1989;77:1037-41.
24. Xu P, Chein YW. Enhanced skin permeability for transdermal drug delivery: Physiopathological & Physicochemical consideration. Crit Rev Ther Drug Carr Sys 1991;8:211-36.
25. Higuchi T. Pro-drugs, molecular structure and percutaneous delivery. In: Roche B, ed. Design of Biopharmaceutical Properties Through Prodrugs and Analogs. Washington DC: APhA, 1977.409-21.
26. Bucks DAW. Skin structure and metabolism: Relevance to the design of cutaneous therapeutics. Pharm Res 1984; 1:148-53.
27. Guy RH, Hadgraft J, Bucks DAW. Transdermal drug delivery and cutaneous metabolism. Xenobiotica 1987;17:325-43.
28. Pannatier PJ, Testa B, Etter JC. The skin as a drug metabolizing organ. Drug Metab Rev 1978;8:319-29.
29. Abraham MH, Chadha HS, Mitchell RC. The factors that influence skin penetration of solutes. J Pharm Pharmacol 1995;47:8-16.
30. Bunge AL, Cleeck RL. A new method for estimation of dermal absorption from chemical exposure: II, Effect of molecular weight and octonol-water partition coefficient. Pharm Res 1995;12:88-95.
31. Ritschel WA Pharmacokinetic and biopharmaceutical aspect of new drug delivery systems. In: Tyle P, ed. Novel Drug Delivery Devices. New York: Marcel Dekker, 1988:59-61.
32. Moore L, Chien YW. Transdermal drug delivery: A review of pharmaceutics, pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carr Sys 1988;4:285-349.
33. Knepp VM, Hadgraft J, Guy RH. Transdermal drug delivery: Problems and possibilities. Crit Rev Ther Drug Carr Sys 1987;4:13-37.
34. Branche Jr GC, Batts Jm, Dowdy VM, Field LS, Francis CH. Improving compliance in an inner-city hypertensive patient population. Am J Med 1991;91:37s-41s.
35. Schenkel L, Muller P, Pethica D. Dermal and transdermal delivery- new insights and perseptives. In: Gunny and Teubner, ed. Second International Symposium of the International Association of Pharmaceutical Technology, 1992.
36. Chandrasekar SK. Controlled release scopolamine for prophylaxis of motion sickness. Drug Dev Ind Pharm 1983;9:627-31.
37. Clissold SP, Heel RC. Transdermal hyoscine (scopolamine): a preliminary review of its pharmacodynamic properties and therapeutic efficacy Drugs 1985;29:189-207.
38. Cronin CM, Sallan SE, Wolfe L. Transdermal scopolamine in motion sickness. Pharmacotherapy 1982;2:29-34.
39. Loper KA, Ready LB, Dorman BH. Prophylactic transdermal scopolamine patches reduce nausea in post-operative patients receiving epidermal morphine. Anaesthesia Analgesia 1989;68:144-6.
40. de Millano PA, Koster RW, Bar FW, Janssen J, de Cock C. Long term efficacy of continuous and intermittent use of transdermal nitroglycerine. Am J Cardiol 1991;68:857-62.
41. Keshary PR, Chien YW. Mechanism of transdermal controlled nitroglycerine administration. I. Development of finite-dose skin permeation system. Drug Dev Ind Pharm 1984;10:883-94.
42. Rayment CM, Kaul AF, Garifield JM. Comparitive acceptance of three transdermal nitroglycerine patches Am J Hosp Pharm 1985;42:1362-5.
43. Schaer DH, Buff LA, Katz RJ. Sustained antianginal effect of transdermal nitroglycerine patches using an overnight 10 hour nitrate free interval. Am J Cardiol 1988;61:46-50.
44. Sjorgren ER: Transdermal nitroglycerine systems: ending the confusion. Crit Care Nur 1983;3:38-42.
45. Lowenthal DT, Matzek KM, McGregor TR.Clinical pharmacokinetics of clonidine. Clin Pharmacokinetics 1988; 14:287-310.
46. MacGregor TR, Matzek KM, Keirns JJ, van Wayjan RGA, van den Ende A, van Tol RGL. Pharmacokinetics of transdermally delivered cloninde. Clin Pharmacol Ther 1985;38:278-84.
47. Shaw JE. Pharmacokinetics of nitroglycerine and clonidine delivered by transdermal route. Am Heart J 1984;108:217-21.
48. Castello-Branco C, Martinez de Osaba MJ, Goanalez-Merlo JPF. The effect of hormone replacement therapy on post-menopausal bone loss. Eur J Obs Gyn Reproduct Biol 1992;44:131-6.
49. Steingold KA, Lauffer L, Chetkowaski RJ, DeFazio JD, Matt DW. Treatment of hot flushes with transdermal estradiol administration. J Clin Endocrinol Metabol 1985;61:622-32.
50. Whitehead MI, Padwick ML, Eandacott J, Pryse-Davies J. Treatment of post menopausal women with transdermal estradiol. Am J Obst Gyn 1985;152:1079-84.
51. Albelin Th, Ehrsam R, Buhler-Reihert IPR, Muller Ph, Thompson A. Effectiveness of transdermal nicotine system in smoking cessation studies. Meth Find Exptl Clin Pharmacol 1989;11:205-14.
52. Transdermal Nicotine Study Group. J Am Med Assoc 1991; 266:3133-8.
53. Matsushima D, Prevo ME, Gorsline J. Absorption and adverse effects following topical and oral administration of three transdermal nicotine products to dogs. J Pharm Sci 1995;84:365-9.
54. Gourlay GK, Kowalaski SR, Plummer JI, Cherry DA, Szekely SM. The efficacy of transdermal fentanyl in the treatment of post operative pain: a double-blind comparison of fentanyl and placebo systems. Pain 1990;40:21-8.
55. Physician's Desk Reference, 46th ed., Medical Economics Data, New Jersey, 1992:866-68, 1133-8, 2386-8.
56. Meidan VM, Walmsley AD, Irwin WJ. Phonophoresis - is it a reality. Int J Pharm 1995;118:129-49.
57. Mitrgotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995;269:850-3.
58. Guy RH. A sweeter life for diabetics. Nature Medicine 1995;11:1132-3.
59. Williams AC, Barry BW. Skin absorption enhancers. Crit Rev Ther Drug Carr Sys 1992;9:305-53.
60. Bundgaard H. Prodrugs as means to improve the delivery of peptide drugs. Adv Drug Del Rev 1992;8:1-38
61. Green PG, Hinz RS, Kim A, Cullunder C, Guy RH. Transdermal Iontophoretic delivery of amino acids and peptides in vitro. J Cont Rel 1992;21:187-90.
62. Brand RM, Guy RH. Iontophoresis of nicotine in vitro: pulsatile drug delivery across the skin? J Cont Rel 1995; 33:285-92.
63. Bommannan DB, Tamada J, Leung L, Potts RD. Effect of electroporation of transdermal iontophoretic delivery of leutinizing hormone-releasing hormone (LHRH) in vitro. Pharm Res 1994;11:1809-14.
64. Ogiso T, Iwaki M, Paku T. Effect of various enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors. J Pharm Sci 1995;84:482-8.
65. Smith SW, Anderson BD. Human skin permeability enhancement by lauric acid under equilibrium aqueous conditions. J Pharm Sci 1995;84:551-6.
66. Naik A, Pechtold LARM, Potts RO, Guy RH. Mechanism of oleic acid-induced skin penetration enhancement in humans. J Cont Rel 1995;37:299-306.
67. Yamashita F, Koyama Y, Kitano M, Takakura Y, Hashida M. Analysis of in vivo skin penetration enhancement by oleic acid based on a two layer diffussion model with polar and nonpolar routes in stratum corneum. Int J Pharm 1995; 117:173-9.
68. Yamana MA, Williams AC, Barry BW. Terpene penetration enhancers in propylene glycol/water co-solvent systems. effectiveness and mechanism of action. J Pharm Pharmacol 1995;47:978-89.
69. Cornell PA, Barry BW. Sesquiterpene components of volatile oils as skin penetration enhancers for the hydrophilic permeant 5-fluorouracil. J Pharm Pharmacol 1994;46: 261-9.
70. Ritschel WA, Sprockel OL. Sorption promoters for topically applied substances. Drugs of Today 1988;24:613-27.
71. Higuchi T, Stella V. Pro-drugs as novel drug delivery systems. Washington DC: American chemical society, 1975.
72. Valia KH, Tojo K, Chien YW. Longterm permeation kinetics of estradiol III. Kinetic analyses of the simultaneous skin permeation and bioconversion of estradiol esters. Drug Dev Ind Pharm 1985;11:1133-73.
73. Tojo K, Valia KH, Chotani G, Chien YW. Longterm permeation kinetics of estradiol IV. A theoritical approach to simultaneous skin permeation and bioconversion of estradiol esters. Drug Dev Ind Pharm 1985;11:1175-93.
74. Chien YW, Valia KH, Doshi UB. Longterm permeation kinetics of estradiol V. development and evaluation of transdermal bioactivated hormone delivery system. Drug Dev Ind Pharm 1985;11:1195-212.
75. Ritschel WA, Barkhaus JK. Feasibility study for transdermal delivery of meperidine. Meth Find Exptl Clin Pharmacol 1988;10:461-6.
76. Ritschel WA, Barkhaus JK. Use of sorption promoters to increase systemic absorption of coumarin from transdermal drug delivery systems. Arzneim.-Forsch /Drug Res 1908;38:1774-7.
77. Ritschel WA, Hussain AS. Influence of selected solvents on penetration of griseofulvin in rat skin, in vitro. Pharm Ind 1988;50:483-6.
78. Ritschel WA, Hussain AS. In vitro skin penetration of griseofulvin in rat and human skin from an ointment dosage form. Arzneim.-Forsch./Drug Res 1988;38:1630-32.
79. Ritschel WA, Nayak PM. Evaluation in vitro and in vivo of dimeticon transdermal therapeutic systems: Influence of propylene glycol on drug release. Arzeim.-Forsch./Drug Res 1987;37:302-306.
80. Santoyo S, Arellano A, Ygartua P, Martin C. Penetration enhancers effect in vitro percutaneous absorption of piroxicam through rat skin. Int J Pharm 1995;117:219-24.
81. Phillips CA, Micjnaik BB. Transdermal delivery of drugs with lipophilicities using azone analogs as dermal penetration enhancers. J Pharm Sci 1995;84:1427-33.
82. Michniak BB, Player MR, Godwin DA, Phillips CA, Sowell, Sr JW. in vitro evaluation of a series of azone analogs as dermal penetration enhancers. Int J Pharm 1995;116: 201-9.
83. Hatanaka T, Katayama K, Koizumi T, Sugibayashi K, Morimoto Y. Time-dependent percutaneous absorption enhancing effect of ethanol. J Cont Rel 1995;33:423-8.
84. Yamana MA, Williams AC, Barry BW. Effects of terpenes and oleic acid as penetration enhancers towards 5-fluorouracil as assessed with time; permeation, partition and differential scanning calorimetry. Int J Pharm 1995; 16:237-51.
85. Cornell PA, Barry BW, Bouwstra JA, Gooris GS. Modes of action of terpene penetration enhancers in human skin: differential scanning calorimetry, small angle x-ray diffraction and enhancer uptake studies. Int J Pharm 1995;127:9-26.
86. Harris WT, Tenjarla SN, Holbrook JM, Smith J, Mead C, Entrekin J. n-Pentyl N-acetylprolinate. A new series of penetration enhancer. J Pharm Sci 1995;84:640-1.
87. Michnaik BB, Player MR, Sowell Sr JW. Synthesis and in vitro transdermal penetration enhancing activity of lactam N-acetic acid esters. J Pharm Sci 1996;85:150-4.
88. Benerjee PS, Ritschel WA. Transdermal permeation of vasopressin. I. Influence of pH, concentration, shaving and surfactant on in vitro permeation Int J Pharm 1989;49:189-97.
89. Benerjee PS, Ritschel WA. Transdermal permeation of vasopressin. II. Influence of azone on in vitro and in vivo permeation. Int J Pharm 1989;49:199-204
90. Leduc S. Electric ions and their use in medicine. London: Rebman, 1908.
91. Chien YW, Siddiqui O, Shi WM, Lelawong P, Liu JC. Direct current iontophoretic transdermal delivery of peptide and protein drugs. J Pharm Sci 1989;78:376-86.
92. Lelawong P, Liu JC, Siddiqui O, Chien YW. Transdermal iontophoretic delivery of arginine-vasopressin. Part 1. Physicochemical consideration. Int J Pharm 1989;56:13-22.
93. Lelawong P, Liu JC, Chien YW. Transdermal iontophoretic delivery of arginine-vasopressin. Part 2. Evaluation of electrical and operational factors. Int J Pharm 1990;61:179-88.
94. Banga AK, Katakam M, Mitra R. Transdermal iontophoretic delivery and degradation of vasopressin across human cadavar skin Int J Pharm 1995;116:211-6.
95. Nakakura M, Terajima M, Kato Y, Hayakawa E, Ito K, Kuroda T. Effect of iontophoretic patterns on in vivo antidiuritic response to desmopressin acetate administered transdermallly. J Drug Targeting 1995;2:487-91.
96. Bumette RR, Marrero D. Comparison between the iontophoretic and passive transport of thyrotropin releasing hormone across excised nude mouse skin. J Pharm Sci 1986;75:738-43.
97. Wearley LL, Tojo K, Chien YW. A numerical approach to study the effect of binding on iontophoretic transport of series of amino acids. J Pharm Sci 1990;79:992-8.
98. Green PG, Hinz RS, Cullander C, Yamane G, Guy RH. Iontophoretic delivery of amino acids and aminoacid derivatives across the skin in vitro. Pharm Res 1991;8:1113-20.
99. Green PG, Hinz RS, Kim A, Szoka FC, Guy RH. Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharm Res 1991;8:1121-7.
100. Mayer BR, Kreis W, Eschbach J, O'Mara V, Rosen S, Sibalis D. Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin Pharmacol Ther 1990;48:340-5.
101. Bodde HE, Verhoef JC, Ponec M.: Transdermal peptide delivery. Biochem Soc Trans 1989;17:943-5.
102. Choi H -K, Flynn GL, Amidon GL. Transdermal delivery of bioactive peptides: the effect of n-decylmethylsulfoxide. pH and inhibitors on enkephalin metabolism and transport. Pharm Res 1990;7:1099-106.
103. Mayer BR, Katzeff HL, Eschbach J, Trimmer J, Zachanas SB, Rosen S, Sibalis D. Transdermal delivery of human insulin to albino rabbits using electrical current. Am J Med Sci 1989;297:321-5.
104. Mayer BR, Kreis W, Eschbach J, O'Mara V, Rosen S, Sibalis D. Successful transdermal administration of therapeutic doses of a polypeptide to normal human volunteers. Clin Pharmacol Ther 1988;44:438-44.
105. Srinivasan V, Su MH, Higuchi WI, Behl CR. Iontophoresis of polypeptides: effect of ethanol pretreatment of human skin. J Pharm Sci 1990;79:885-7.
106. Srinivasan V, Higuchi WI, Sims SM, Ghanem AH, Behl CR. Transdermal iontophoretic drug delivery: Mechanistic analysis and application to polypeptide delivery. J Pharm Sci 1989;78:370-5.
107. Miller LL, Kolaskie CJ, Smith GA, Ruer J. Transdermal iontophoresis of gonodotropin releasing hormone (LHRH) and two anaologs. J Pharm Sci 1990;79:490-3.
108. Riviere JE, Nancy A, Riviere -M, Rogers RA, Bommannan D, Tamada JA, Potts RO. Pulsatile transdermal delivery of LHRH using electroporation. Drug delivery and toxicology. J Cont Rel 1995,36:229-33.
109. Heit MC, Williams PL, Jayes FL, Riviere JE. Transdermal iontophoretic peptide delivery: in vitro and in vivo studies luteinizing hormone releasing hormone. J Pharm Sci 1993;82:240-3.
110. Heit MC, Monteiro-Reviere NA, Jayes FL, Riviere JE. Transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH): effect of repeat administration. Pharm Res 1994;11:1000-3.
111. Shapiro RL, Pence, TV, Warwick WJ. Insulin iontophoresis in cystic fibrosis. Proc Soc Exp Biol Med 1975;149:592-3.
112. Kari B. Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes 1986;35:217-21.
113. Stephan RL, Petelenz TJ, Jacobsen SC. Potential novel methods for insulin administration. Biomed Biochem Acta 1984;43:553-8.
114. Siddiqui O, Sun Y, Liu J.-C, Chien YW. Facilitated transport of insulin. J Pharm Sci 1987;76:341-5.
115. Banga AK, Chein YW. Characterization of in vitro transdermal iontophoretic delivery of insulin. Drug Dev Ind Pharm 1993;19:2069-87.
116. Langkjoer L, Brange J, Grodsky GM, Guy RH. Transdermal delivery of monomeric insulin analogues by iontophoresis. Proc Int Sym Cont Rel Bioact Mater 1994;21:321-9.
117. Santi P, Guy RH. Reverse iontophoresis-Parameters determining electroosmotic flow: I. pH and ionic strength. J Cont Rel 1996;38:159-65.
118. Tamada JA, Bohannon NJV, Potts RO. Measurment of glucose in diabetic subjects using noninvasive transdermal extraction. Nature Medicine 1995;11:1198-1201.
119. Chandrashaker G, Bhat R, Singh MK, Udupa N. Optimization of parameters for transdermal permeation of insulin. Ind J Pharm Sci 1994;56:205-9.
120. Burnette RR, Ongpipattanakul B Characterization of permselective properties of excised human skin during iontrophoresis. J Pharm Sci 1987;76:765-73.
121. Clemessay M, Couarraze G, Seven B, Puisieux F. Mechanism involved in iontophoretic transport of angiotensin. Pharm Res 1995;12:998-1002.
122. Clemessay M, Couarraze G, Beven B, Puisieux F. Preservation of skin permeability during in vitro iontophoretic experiments. Int J Pharm 1994;101.219-26.
123. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin. A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA. 1993;90:10504-8.
124. Prausnitz MR, Pliquett U, Langer R, Weaver JC. Rapid temporal control of transdermal drug delivery by electroporation. Pharm Res 1994;11:1809-14.
125. Pliquett U, Langer R, Weaver JC. Changes in the passive electrical properties of human stratum corneum due to electroporation. Biochimica Biophysica Acta (Biomembranes). 1995;1239:111-21.
126. Prausnitz MR, Edelman ER, Gimm JA, Langer R, Weaver JC. Transdermal delivery of heparin by skin electroporation. Bio-Technology 1995;13:1205-9.
127. Pliquett U, Weaver JC. Transport of a charged molecule across the human epidermis due to electroporation. J Cont Rel 1996;38:1-10.
128. Riviere JE, Nancy A, Riviere -M, Rogers RA, Bommannan D, Tamada JA, Potts RO. Pulsatile transdermal delivery of LHRH using electroporation: Drug delivery and toxicology. J Cont Rel 1995;36:229-33.
129. Tachibana K. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm Res 1992;9:952-4.
130. Bellantone NH, Rim S, Francoer ML, Rasadi B. Enhanced percutaneous absorption via iontophoresis I. Evaluation of in vitro system and transport model compounds. Int J Pharm 1986;30:63-72.
131. Chu LC, Gale RM, Schmitt LG, Shaw JE Nitroglycerine concentration in plasma - comparison between transdermal therapeutic system and ointment. Angiology 1984;35:545-52.
132. Reichek N, Goldstein RE, Redwood DR, Epstein SE. Sustained effects of nitroglycerine ointment in patients with angina pectoris. Circulation 1974;50:348-52.
133. Denyer SP, Huge WB, O'Brien M. Metabolism of glycerl trinitrate by skin staphylococci. J Pharm Pharmacol 1984;36:61-4.
134. Bonn R, Hadgraft J, Wolff HM. Nitroglycerine TTS. biopharmaceutical and pharmacological aspects of transdermal therapy. In: Rezakovic D, Alpert JS, eds. Nitrate Therapy and Nitrate tolerance. Current concepts and controversies. Switzerland: S. Karger AG, Basel, 1993:224-51.
135. Wolff M, Cordes G, Luckow V. in vitro and in vivo-release of nitroglycerine from new transdermal therapeutic system. Pharm Res 1985;2:23-9.
136. Cronin CM, Bonn, R, Sallan SE, Wolfe L. Comparitive evaluation of the three commerciallly available transdermal nitroglycerine systems. Drug Intell Clin Pharm 1987;21:642-8.
137. Bennett ED, Davis AL. A haemodynamic and pharmacokinetic study to assess a new transdermal nitroglycerine preparation in normal subjects. Eur J Pharmacol 1984; 22:473-9.
138. Georgopoulos AJ, Markis A, Georgiadis H. Therapeutic efficacy of a new transdermal system containing nitroglycerine in patients with angina pectoris. Eur J Pharmcol 1982; 22.481-6.
139. Demonts H, Glasser SP. Intermittent transdermal nitroglycerine therapy in the chronic stable angina. Am J Cardiol 1989;60:271-5.
140. Elkayam U. Tolerance to organic nitrites - evidence, mechanism, clinical relevence and stratigies for prevention. Ann Intern Med 1991;114:667-77.
141. Hadgraft J. Pharmaceutical aspects of transdermal nitroglycerine. Int J Pharm 1996;135:1-11.
142. Monkhouse DC, Huq AS. Transdermal drug delivery: Problems and Promises. Drug Dev Ind Pharm 1988; 14:183-209.
143. Abraham J. Nitrate tolerance and dependency. Am Heart J 1980;99 113-8.
144. Abraham J. Transdermal nitroglycerine and tolerance. Ann Intern Med 1983;104:424-8.
145. Abraham J. Tolerance of organic nitrates. Circulation 1986,74:1181-6.
146. Hadgraft J, Wolff M, Bonn R, Cordes G. Development of biphasic transdermal nitroglycerine delivery systems. Int J Pharm 1990;64:187-94.
147. Brouangh, RL. Determination of penetration absorption by in-vitro technique.In: percutaneous absorption. Brouangh RL, Maibach HI, editors. New York: Marcel Dekker, 1985:267-79.
148. Lin, R-Y., Hsu, C-W. and Chein, YW. A method to predict the transdermal permeability of amino acids and dipeptides through porcine skin. J Cont Rel 1996;38:229-34.
149. Wester RC, Noonan PK. Relevance of animal models for percutaneous absorption. Int J Pharm 1980;7:99-110.
150. Bronaugh RL, Stewart RF, Congdon ER. (1982) Methods for in vitro percutaneous absorption studies II. Animal models for human skin. Toxicol App Pharmacol 1982;62:481-8.
151. Niazy, EM. Differences in penetration-enhancing effect of azone through excised rabbit, rat, hairless mouse, guinea pig and human skins. Int J Pharm 1996;130:225-30.
152. Wester RC, Maibach HI. Animal models for percutaneous absorption. In Maibach HI, Lowe KI, eds. Models in Dermatology, Vol. 2, Basal: Karger, 1985:159-69.
153. Franz, TJ. The finite dose technique as a valid in vitro model for the study of percutaneous absorption in man. Curr Problems Dermatol 1978;7:58-68.
154. Sato K, Sugibayashi K, Morimoto Y, Omiya H, Enomoto N. Prediction of in vitro human skin permeability of nicorandil from animal data. J Pharm Pharmacol 1989; 41:379-83.
155. Wester RC, Noonan PK, Maibach HI. Variations in percutaneous absorption of testosterone in rhesus monkey due to anatomic site of application and frequency of application. Archs Derm 1980;267:229-35.
156. Bartek MJ, La Budde JA. Percutaneous absorption in vitro. In: Maibach HI, editor. Animal models in dermatology. New York: Churchill Livingstone, 1975:103-20
157. Wester RC, Maibach HI. Relationship of topical dose and percutaneous absorption in rehesus monkey and man. J Invest Dermatol 1976;67:518-20.
158. Scheuplein RJ. Mechanisms of percutaneous absorption I: routes of penetration and influence of solubility. J Invest Dermatol 1965;45:334-6.
159. McGreesh AH. Percutaneous toxicity. Toxicol App Pharmacol 1965;2:20-6.
160. Vinson LJ, Singer EJ, Koehler R, Lehman MD, Masurat T. The nature of epidermal carrier and some factors influencing skin permeability. Toxicol App Pharmacol 1965;7:7-19.
161. Marzuli FN, Brown DWC, Maibach HI. Techniques for studying skin penetration. Toxicol App Pharmacol 1969;2:76-83.
162. Cambell P, Watanabe T, Chandrasekaran SK Comparison of in vitro skin permeability of scopalamine in rat rabbit and man. Fed Am Soc Expt Biol (Fed. Proc.)1976;35:639-41.
163. Chowhan ZT, Pritchard R. Effect of surfactants on percutaneous absorption of naproxen I: Comparisons of rabbit, rat and human excised skin. J Pharm Sci 1978;67:1272-4.
164. Scott RC, Walker M, Dugard PH. A comparison of the in vitro permeability properties of human and some laboratory animal skins. Int J Cosm Sci 1986;8:189-94.
165. Cairncross C, Ackermann C. Permeation of digoxin through skin in vitro. Int J Pharm 1985;27:361-2.